Rituximab: Emerging treatment strategies of immune-mediated glomerular disease

Andrea G. Kattah, Fernando C. Fervenza

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


The use of monoclonal antibodies in the treatment of malignancy and autoimmune diseases has rapidly expanded in the last decade. Rituximab, a monoclonal antibody to the CD20 antigen on B cells, was first approved by the US FDA in 1997 to treat non-Hodgkin's B-cell lymphoma. It is now used, however, for a variety of diseases in both on- and off-label uses. It was approved by the FDA for use in refractory rheumatoid arthritis in 2007, and in April 2011 it was approved for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitides (including granulomatosis with polyangiitis [Wegener's granulomatosis] and microscopic polyangiitis), based on the promising results of the RAVE trial. Within the field of nephrology, in addition to its use in anti-neutrophil cytoplasmic antibody-associated vasculitides, it is has been used in the treatment of membranous nephropathy, membranoproliferative glomerulonephritis and lupus nephritis.

Original languageEnglish (US)
Pages (from-to)413-421
Number of pages9
JournalExpert review of clinical immunology
Issue number5
StatePublished - Jul 2012


  • ANCA
  • lupus nephritis
  • membranoproliferative glomerulonephritis
  • membranous nephropathy
  • rituximab
  • vasculitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Rituximab: Emerging treatment strategies of immune-mediated glomerular disease'. Together they form a unique fingerprint.

Cite this